Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1995-05-18
2010-10-05
Romeo, David S (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S012200, C435S007100
Reexamination Certificate
active
07807783
ABSTRACT:
This invention provides a novel protein designated FADD, FADD fragments, and anti-FADD antibodies which are useful to modulate Fas-associated cellular functions such as apoptosis. Also provided are nucleic acid molecules coding for these proteins and antibodies as well as process for making these compositions. Further provided are diagnostic and therapeutic methods for these compositions.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5258454 (1993-11-01), Berg et al.
patent: 5674734 (1997-10-01), Leder et al.
patent: WO 93/25685 (1993-12-01), None
patent: WO 93/25694 (1993-12-01), None
patent: WO 93/18317 (1994-08-01), None
patent: WO 94/21817 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/25621 (1994-11-01), None
patent: WO 94/27583 (1994-12-01), None
patent: WO 95/31544 (1995-11-01), None
patent: WO 96/01642 (1996-01-01), None
patent: WO 96/18641 (1996-06-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 96/25945 (1996-08-01), None
patent: WO 96/36698 (1996-11-01), None
patent: WO 96/40713 (1996-12-01), None
patent: WO 97/03998 (1997-02-01), None
patent: WO 97/18313 (1997-05-01), None
patent: WO 98/03648 (1998-01-01), None
Cell vol. 74 Sep. 10, 1993, Tartaglia et al. pp. 845-853.
J. Biol Chem vol. 269 No. 36, Sep. 9, 1994, Song et al. pp. 22492-22495.
J. Biol Chem vol. 268 No. 15, May 25, 1993, Itoh et al. pp. 10932-10937.
Febs Letters vol. 337 Jan. 10, 1994, Mackawa et al. pp. 200-206.
Cell vol. 58 Aug. 25, 1989, Morrison et al. pp. 649-657.
Itoh N; Yonehara S; Ishii A; Yonehara M; Mizushima S; Sameshima M; Hase A; Seto Y; Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. CELL, (Jul. 26, 1991) 66 (2) 233-43, Jul. 1991.
Boldin et al. Self-association of the “death domains” of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. Journal of Biological Chemistry, (Jan. 6, 1995) 270 (1) 387-91, Jan. 1995.
Daniel et al. Virology, (Aug. 1, 1994) 202 (2) 540-549, Aug. 1994.
Sambrook et al. Molecular Cloning: A Laboratory Manual Second Edition vols. 1, 2 and 3. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, U.S.A. Nov. 1989, Chapter 17, Nov. 1989.
Alberts et al., Molecular Biology of the Cell, Jan. 1994, Garland Publishing, Inc., New York, NY, p. 119, Jan. 1994.
Vaux et al., “An evolutionary perspective on apoptosis”Cell(1994) 76:777-779.
Ellis et al., “Mechanisms and functions of cell death”Ann. Rev. Cell Biol.(1991) 7:663-698.
Tomei et al., “Apoptosis: The Molecular Basis of Cell Death”Current Communications in Cell&Molecular Biology 3(1991) Cold Spring Harbor Press, New York. A title page and table of contents were previously enclosed.
Tomei et al., “Apoptosis II: The Molecular Basis of Cell Death”Current Communications in Cell and Molecular Biology 8(1994) Cold Spring Harbor Press, New York. A title page and table of contents were previously enclosed.
Duvall et al., “Death and the cell”Immunol. Today(1986) 7:115-119.
Cohen, “Apoptosis”Immunol. Today(1993) 14:126-130.
Brunner et al., “Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas”Nature(1995) 373:441-444.
Dhein et al., “Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)”Nature(1995) 373:438-441.
Ju et al., “Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation”Nature(1995) 373:444-448.
Itoh et al., “The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis”Cell(1991) 66:233-243.
Tewari et al., “Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxviruscrmAgene product”J. Biol. Chem.(1995) 270:3255-3260.
Yuan et al., “TheC. eleganscell death geneced-3encodes a protein similar to mammalian interleukin-1β-converting enzyme”Cell(1993) 75:641-652.
Cerretti et al., “Molecular cloning of the interleukin-1βconverting enzyme”Science(1992) 256:97-100.
Thornberry et al., “A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes”Nature(1992) 356:768-774.
Miura et al., “Induction of apoptosis in fibroblasts by IL-β-converting enzyme, a mammalian homolog of theC. eleganscell death geneced-3” Cell(1993) 75:653-660.
Baglioni, “Mechanisms of cytotoxicity, cytolysis, and growth stimulation by TNF”Tumor Necrisis Factors. The Molecules and Their Emerging Role in Medicine(1992) B. Beutler, M.D., ed., Raven Press, New York. A title page and table of contents were previously enclosed.
Yonehara et al.. “A cell-killing monoclonal antibody (Anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor”J. Exp. Med.(1989) 169:1747-1756.
Trauth et al., “Monoclonal antibody-mediated tumor regression by induction of apoptosis”Science(1989) 245:301-305.
Watanabe-Fukunaga et al., “Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis”Nature(1992) 356:314-317.
Tartaglia et al., “Two TNF receptors”Immunol. Today(1992) 13:151-153.
Boldin et al., “Self-association of the ‘death domains’ of the p55 tumor necrosis factor (TNF) receptor and Fas/AP01 prompts signaling for TNF and Fas/APO1 effects”J. Biol. Chem.(1995) 270:387-391.
Song, “Aggregation of the intracellular domain of the Type I tumor necrosis factor receptor defined by the two-hybrid system”J. Biol Chem.(1994) 269:22492-22495.
Itoh et al., “A novel protein domain required for apoptosis”J. Biol. Chem.(1993) 268:10932-10937.
Bordignon et al., “Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells”Proc. Natl. Acad. Sci. USA(1989) 86:6748-6752.
Culver et al., “Lymphocytes as cellular vehicles for gene therapy in mouse and man”Proc. Natl. Acad. Sci. USA(1991) 88:3155-3159.
Rill et al., “An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer”Blood(1992) 79:2694-2700.
Anderson, “Human gene therapy”Science(1992) 256:808-813.
Steplewski et al., “Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants”Proc. Natl. Acad. Sci. USA(1985) 82:8653-8657.
Spira et al., “The identification of monoclonal class switch variants by Sib selection and an ELISA assay”J. Immunol. Meth.(1984) 74:307-315.
Oi et al., “Chimeric antibodies”BioTechniques(1986) 4:214-221.
Herlyn et al., “Anti-idiotypic antibodies bear the internal image of a human tumor antigen”Science(1986) 232:100-102.
Spriggs et al., “Tumor necrosis factor expression in human epithelial tumor cell lines”J. Clin. Invest.(1988) 81:455-460.
Watanabe-Fukunaga et al., “The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen”J. Immun.(1992) 148:1274-1279.
Owen-Schaub et al., “Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness”Cancer Res.(1994) 54:1580-1586.
Opipari, Jr. et al., “The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity”J. Biol. Chem.(1992) 267:12424-12427.
Lum et al., “Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients”Bone Marrow Transplantation(1993) 12:565-571.
H
Dixit Vishva M.
O'Rourke Karen
Casimir Jones SC
Romeo David S
The Regents of the University of Michigan
LandOfFree
Methods and compositions for regulating FAS-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for regulating FAS-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for regulating FAS-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226166